Esperion Offers Results Of Five Studies Of Heart DrugPlymouth-based Esperion Therapeutics Monday announced the results from a Phase 1 study and four preclinical studies for its heart disease drug candidate ETC-1002. Initial results look promising.
Esperion Starts Phase 2 Trial Of Cholesterol Buster

More From CBS Detroit

Hump Day Drinks: 8 Cheery Cocktail RecipesNow that you've made it through half the work week, it's time to celebrate!
Daily J

Watch & Listen